We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Portable UTI Testing Platform Brings Lab-Quality Molecular Diagnostics to Point-Of-Care Settings

By LabMedica International staff writers
Posted on 25 Apr 2023

Urinary tract infections (UTIs) are among the most prevalent bacterial infections worldwide, with 90% of patients being women and the risk increasing with age. More...

UTIs can be painful, debilitating, and potentially lead to severe long-term complications, such as sepsis. However, suitable point-of-care diagnostic tools are lacking, leading to frequent over- and underdiagnosis. UTI treatments account for 10-20% of community antibiotic prescriptions, but many of these antibiotics are prescribed unnecessarily, contributing to the spread of antibiotic resistance. Now, a new point-of-care UTI test can assist clinicians in making evidence-based decisions for UTI patients.

Llusern Scientific (Wales, UK) is launching its UTI assay panel which can test for up to six UTIs at the point-of-care, revolutionizing the way clinicians test for UTIs. The UTI assay panel will test for Escherichia coli (E-coli), Klebsiella spp, Proteus mirabilis, Staphylococcus saprophyticus, Enterococcus spp, and Pseudomonas aeruginosa. This innovative test delivers results in just 40 minutes, avoiding decisions based on ambiguous clinical symptoms or imprecise urine dipstick tests. Clinical results thus far indicate 93% sensitivity and 99% specificity for the test. Additionally, the portable, user-friendly test requires no sample processing, making it adaptable for use in various patient populations and settings, potentially including community and emergency care.

Llusern’s UTI assay panel will run on Lodestar DX, a portable molecular platform designed for UTI and respiratory disease testing that provides lab-accurate results in 30 minutes. This cost-effective technology enables users to perform Loop-mediated isothermal amplification (LAMP) reactions conveniently. The method allows for the amplification and detection of DNA or RNA in a wide array of bacterial and viral targets. Lodestar DX uses an internal algorithm to determine the positivity or negativity of a LAMP reaction, and this algorithm is compatible with numerous LAMP reactions. The system outputs real-time fluorescent reaction data that can be directly captured on a PC and stored for later offline analysis. Capable of running eight reactions simultaneously, Lodestar DX can be operated flexibly based on user requirements. It can be powered by a mains supply using its power adapter or a 15Vdc source like a standard vehicle lighter plug, enabling its use in remote locations.

 


Gold Member
Automated MALDI-TOF MS System
EXS 3000
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.